{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:04:30Z","timestamp":1791345870572,"version":"4.3.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS113828"],"award-info":[{"award-number":["R01NS113828"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00415-024-12861-9","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T13:05:03Z","timestamp":1736946303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["MOG antibody-associated disease epidemiology in Olmsted County, USA, and Martinique"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-2410","authenticated-orcid":false,"given":"Laura","family":"Cacciaguerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-663X","authenticated-orcid":false,"given":"Elia","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2302-7970","authenticated-orcid":false,"given":"Isabelle","family":"Komla-Soukha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3610-6945","authenticated-orcid":false,"given":"Carin Y.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6400-7760","authenticated-orcid":false,"given":"Vyanka","family":"Redenbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Fryer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6933-8913","authenticated-orcid":false,"given":"Jan-Mendelt","family":"Tillema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0751-8967","authenticated-orcid":false,"given":"Nisa","family":"Vorasoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-6450","authenticated-orcid":false,"given":"Nanthaya","family":"Tisavipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0607-904X","authenticated-orcid":false,"given":"Smathorn","family":"Thakolwiboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-9045","authenticated-orcid":false,"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6856-8143","authenticated-orcid":false,"given":"Andrew","family":"McKeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8141-2394","authenticated-orcid":false,"given":"W. Oliver","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhun H.","family":"Kantarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-935X","authenticated-orcid":false,"given":"B. Mark","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena A.","family":"Tajfirouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Chodnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Mandrekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5070-1196","authenticated-orcid":false,"given":"Claudia F.","family":"Lucchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5653-5600","authenticated-orcid":false,"given":"Sebastian A.","family":"Lopez-Chiriboga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6446-1146","authenticated-orcid":false,"given":"Nabeela","family":"Nathoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2860-6314","authenticated-orcid":false,"given":"Nycole K.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle F.","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Sagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-2910","authenticated-orcid":false,"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"12861_CR1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 22:268\u2013282","journal-title":"Lancet Neurol"},{"key":"12861_CR2","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","volume":"13","author":"E Sechi","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, Lopez-Chiriboga AS, Pittock SJ, Flanagan EP (2022) Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol 13:885218","journal-title":"Front Neurol"},{"key":"12861_CR3","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","volume":"92","author":"PJ Waters","year":"2019","unstructured":"Waters PJ, Komorowski L, Woodhall M, Lederer S, Majed M, Fryer J, Mills J, Flanagan EP, Irani SR, Kunchok AC, McKeon A, Pittock SJ (2019) A multicenter comparison of MOG-IgG cell-based assays. Neurology 92:e1250\u2013e1255","journal-title":"Neurology"},{"issue":"2","key":"12861_CR4","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000674","volume":"7","author":"M Reindl","year":"2020","unstructured":"Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, Fryer JP, Mills J, Teegen B, Mindorf S, Ritter N, Krummrei U, Stocker W, Eggert J, Flanagan EP, Ramberger M, Hegen H, Rostasy K, Berger T, Leite MI, Palace J, Irani SR, Dale RC, Probst C, Probst M, Brilot F, Pittock SJ, Waters P (2020) International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 7(2):e674","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12861_CR5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","volume":"78","author":"E Sechi","year":"2021","unstructured":"Sechi E, Buciuc M, Pittock SJ, Chen JJ, Fryer JP, Jenkins SM, Budhram A, Weinshenker BG, Lopez-Chiriboga AS, Tillema JM, McKeon A, Mills JR, Tobin WO, Flanagan EP (2021) Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol 78:741\u2013746","journal-title":"JAMA Neurol"},{"key":"12861_CR6","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","volume":"91","author":"K O'Connell","year":"2020","unstructured":"O\u2019Connell K, Hamilton-Shield A, Woodhall M, Messina S, Mariano R, Waters P, Ramdas S, Leite MI, Palace J (2020) Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry 91:1126\u20131128","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12861_CR7","volume":"63","author":"R Orlandi","year":"2022","unstructured":"Orlandi R, Mariotto S, Gajofatto A (2022) Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona. Italy Mult Scler Relat Disord 63:103884","journal-title":"Italy Mult Scler Relat Disord"},{"key":"12861_CR8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","volume":"26","author":"CL de Mol","year":"2020","unstructured":"de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, Hamann D, Hintzen RQ (2020) The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler 26:806\u2013814","journal-title":"Mult Scler"},{"key":"12861_CR9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/13524585231156736","volume":"29","author":"M Nakamura","year":"2023","unstructured":"Nakamura M, Ogawa R, Fujimori J, Uzawa A, Sato Y, Nagashima K, Kuriyama N, Kuwabara S, Nakashima I (2023) Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. Mult Scler 29:530\u2013539","journal-title":"Mult Scler"},{"key":"12861_CR10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ncn3.12479","volume":"9","author":"K Tan","year":"2021","unstructured":"Tan K, Yeo T, Yong KP, Thomas T, Wang F, Tye J, Quek AML (2021) Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singapore\u2014epidemiology and evolution of an emerging subspecialty. Neurol Clin Neurosci 9:259\u2013265","journal-title":"Neurol Clin Neurosci"},{"key":"12861_CR11","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104511","volume":"70","author":"N Tisavipat","year":"2023","unstructured":"Tisavipat N, Jitpratoom P, Siritho S, Prayoonwiwat N, Apiwattanakul M, Boonyasiri A, Rattanathamsakul N, Jitprapaikulsan J (2023) The epidemiology and burden of neuromyelitis optica spectrum disorder, multiple sclerosis, and MOG antibody-associated disease in a province in Thailand: a population-based study. Mult Scler Relat Disord 70:104511","journal-title":"Mult Scler Relat Disord"},{"key":"12861_CR12","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/ije\/dys195","volume":"41","author":"JL St Sauver","year":"2012","unstructured":"St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Pankratz JJ, Brue SM, Rocca WA (2012) Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol 41:1614\u20131624","journal-title":"Int J Epidemiol"},{"key":"12861_CR13","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/ije\/dyx268","volume":"47","author":"WA Rocca","year":"2018","unstructured":"Rocca WA, Grossardt BR, Brue SM, Bock-Goodner CM, Chamberlain AM, Wilson PM, Finney Rutten LJ, St Sauver JL (2018) Data Resource Profile: expansion of the Rochester Epidemiology Project medical records-linkage system (E-REP). Int J Epidemiol 47:368\u2013368j","journal-title":"Int J Epidemiol"},{"key":"12861_CR14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","volume":"79","author":"EP Flanagan","year":"2016","unstructured":"Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Robinson AB, Pittock SJ (2016) Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 79:775\u2013783","journal-title":"Ann Neurol"},{"key":"12861_CR15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2020.07.014","volume":"220","author":"MB Hassan","year":"2020","unstructured":"Hassan MB, Stern C, Flanagan EP, Pittock SJ, Kunchok A, Foster RC, Jitprapaikulsan J, Hodge DO, Bhatti MT, Chen JJ (2020) Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am J Ophthalmol 220:110\u2013114","journal-title":"Am J Ophthalmol"},{"key":"12861_CR16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.25131","volume":"83","author":"D Dubey","year":"2018","unstructured":"Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, Gadoth A, Smith CY, Bryant SC, Klein CJ, Aksamit AJ, Toledano M, Boeve BF, Tillema JM, Flanagan EP (2018) Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 83:166\u2013177","journal-title":"Ann Neurol"},{"key":"12861_CR17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ana.26931","volume":"96","author":"V Redenbaugh","year":"2024","unstructured":"Redenbaugh V, Fryer JP, Cacciaguerra L, Chen JJ, Greenwood TM, Thakolwiboon S, Majed M, Chia NH, Gilligan M, McKeon A, Mills JR, Lopez Chiriboga AS, Tillema J-M, Abdulrahman Y, Vorasoot N, Valencia Sanchez C, Tajfirouz DA, Toledano M, Zekeridou A, Dubey D, Gombolay GY, Capar\u00f3-Zamalloa C, Kister I, Pittock SJ, Flanagan EP (2024) Diagnostic utility of MOG antibody testing in cerebrospinal fluid. Ann Neurol 96(1):34\u201345","journal-title":"Ann Neurol"},{"key":"12861_CR18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"PJ Waters","year":"2012","unstructured":"Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar JN, Vincent A, Bar-Or A, Pittock SJ (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78:665\u2013671 (discussion 669)","journal-title":"Neurology"},{"key":"12861_CR19","first-page":"205521732110526","volume":"7","author":"V Redenbaugh","year":"2021","unstructured":"Redenbaugh V, Montalvo M, Sechi E, Buciuc M, Fryer JP, McKeon A, Lennon VA, Mills JR, Weinshenker BG, Wingerchuk DM, Chen JJ, Tariq Bhatti M, Lopez Chiriboga AS, Pittock SJ, Flanagan EP (2021) Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin 7:20552173211052656","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"12861_CR20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2023-333227","volume":"95","author":"AG Filippatou","year":"2024","unstructured":"Filippatou AG, Said Y, Chen H, Vasileiou ES, Ahmadi G, Sotirchos ES (2024) Validation of the international MOGAD panel proposed criteria: a single-centre US study. J Neurol Neurosurg Psychiatry 95(9):870\u2013873","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"12861_CR21","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200183","volume":"11","author":"M Forcadela","year":"2024","unstructured":"Forcadela M, Rocchi C, San Martin D, Gibbons EL, Wells D, Woodhall MR, Waters PJ, Huda S, Hamid S (2024) Timing of MOG-IgG testing Is Key to 2023 MOGAD diagnostic criteria. Neurol Neuroimmunol Neuroinflamm 11(1):e200183","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12861_CR22","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1177\/13524585231198754","volume":"29","author":"KH Kim","year":"2023","unstructured":"Kim KH, Kim SH, Park NY, Hyun JW, Kim HJ (2023) Validation of the international MOGAD panel proposed criteria. Mult Scler 29:1680\u20131683","journal-title":"Mult Scler"},{"key":"12861_CR23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMOD (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"12861_CR24","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG, Workgroup USMSP (2019) The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 92:e1029\u2013e1040","journal-title":"Neurology"},{"key":"12861_CR25","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200214","volume":"11","author":"N Tisavipat","year":"2024","unstructured":"Tisavipat N, Stiebel-Kalish H, Palevski D, Bialer OY, Moss HE, Chaitanuwong P, Padungkiatsagul T, Henderson AD, Sotirchos ES, Singh S, Salman AR, Tajfirouz DA, Chodnicki KD, Pittock SJ, Flanagan EP, Chen JJ (2024) Acute optic neuropathy in older adults: differentiating between MOGAD optic neuritis and nonarteritic anterior ischemic optic neuropathy. Neurol Neuroimmunol Neuroinflamm 11:e200214","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12861_CR26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","volume":"11","author":"JY Hor","year":"2020","unstructured":"Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, Pittock SJ, Palace J, Wingerchuk DM, Behne JM, Yeaman MR, Fujihara K (2020) Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 11:501","journal-title":"Front Neurol"},{"key":"12861_CR27","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P (2020) Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler 26:1816\u20131821","journal-title":"Mult Scler"},{"key":"12861_CR28","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","volume":"77","author":"AS Lopez-Chiriboga","year":"2020","unstructured":"Lopez-Chiriboga AS, Sechi E, Buciuc M, Chen JJ, Pittock SJ, Lucchinetti CF, Flanagan EP (2020) Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder. JAMA Neurol 77:1575\u20131577","journal-title":"JAMA Neurol"},{"key":"12861_CR29","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/ene.14746","volume":"28","author":"R Deschamps","year":"2021","unstructured":"Deschamps R, Pique J, Ayrignac X, Collongues N, Audoin B, Zephir H, Ciron J, Cohen M, Aboab J, Mathey G, Derache N, Laplaud D, Thouvenot E, Bourre B, Ruet A, Durand-Dubief F, Touitou V, Vignal-Clermont C, Papeix C, Gout O, Marignier R, Maillart E, Group Ns (2021) The long-term outcome of MOGAD: an observational national cohort study of 61 patients. Eur J Neurol 28:1659\u20131664","journal-title":"Eur J Neurol"},{"key":"12861_CR30","first-page":"e1351","volume":"97","author":"HH Zhao-Fleming","year":"2021","unstructured":"Zhao-Fleming HH, Valencia Sanchez C, Sechi E, Inbarasu J, Wijdicks EF, Pittock SJ, Chen JJ, Wingerchuk DM, Weinshenker BG, Lopez-Chiriboga S, Dubey D, Tillema JM, Toledano M, Yadav H, Flanagan EP (2021) CNS Demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies. Neurology 97:e1351\u2013e1358","journal-title":"Neurology"},{"key":"12861_CR31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","volume":"89","author":"A Cobo-Calvo","year":"2021","unstructured":"Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, Papeix C, Audoin B, Lepine AF, Maurey H, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Meyer P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Horello P, Tintore M, De Seze J, Vukusic S, Deiva K, Marignier R, Nomadmus K, Groups Os (2021) Clinical Features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 89:30\u201341","journal-title":"Ann Neurol"},{"key":"12861_CR32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","volume":"5","author":"C Satukijchai","year":"2022","unstructured":"Satukijchai C, Mariano R, Messina S, Sa M, Woodhall MR, Robertson NP, Ming L, Wassmer E, Kneen R, Huda S, Jacob A, Blain C, Halfpenny C, Hemingway C, O\u2019Sullivan E, Hobart J, Fisniku LK, Martin R, Dopson R, Cooper SA, Williams V, Waters PJ, Ramdas S, Leite MI, Palace J (2022) Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. JAMA Netw Open 5:e2142780","journal-title":"JAMA Netw Open"},{"key":"12861_CR33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/jnnp-2022-330237","volume":"94","author":"M Gastaldi","year":"2023","unstructured":"Gastaldi M, Foiadelli T, Greco G, Scaranzin S, Rigoni E, Masciocchi S, Ferrari S, Mancinelli C, Brambilla L, Mancardi M, Giacomini T, Ferraro D, Della Corte M, Gallo A, Di Filippo M, Benedetti L, Novi G, Versino M, Banfi P, Iorio R, Moiola L, Turco E, Sartori S, Nosadini M, Ruggieri M, Savasta S, Colombo E, Ballante E, Jarius S, Mariotto S, Franciotta D, Group Ns (2023) Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study. J Neurol Neurosurg Psychiatry 94:201\u2013210","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12861_CR34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","volume":"77","author":"P Waters","year":"2020","unstructured":"Waters P, Fadda G, Woodhall M, O\u2019Mahony J, Brown RA, Castro DA, Longoni G, Irani SR, Sun B, Yeh EA, Marrie RA, Arnold DL, Banwell B, Bar-Or A, Canadian Pediatric Demyelinating Disease N (2020) Serial Anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol 77:82\u201393","journal-title":"JAMA Neurol"},{"key":"12861_CR35","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","volume":"75","author":"AS Lopez-Chiriboga","year":"2018","unstructured":"Lopez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ (2018) Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol 75:1355\u20131363","journal-title":"JAMA Neurol"},{"key":"12861_CR36","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/WNL.0000000000007077","volume":"92","author":"EA Yeh","year":"2019","unstructured":"Yeh EA, Nakashima I (2019) Live-cell based assays are the gold standard for anti-MOG-Ab testing. Neurology 92:501\u2013502","journal-title":"Neurology"},{"key":"12861_CR37","doi-asserted-by":"crossref","first-page":"e1867","DOI":"10.1212\/WNL.0000000000008479","volume":"93","author":"S Mariotto","year":"2019","unstructured":"Mariotto S, Gajofatto A, Batzu L, Delogu R, Sechi G, Leoni S, Pirastru MI, Bonetti B, Zanoni M, Alberti D, Schanda K, Monaco S, Reindl M, Ferrari S (2019) Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology 93:e1867\u2013e1872","journal-title":"Neurology"},{"key":"12861_CR38","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1093\/brain\/awad122","volume":"146","author":"Y Matsumoto","year":"2023","unstructured":"Matsumoto Y, Kaneko K, Takahashi T, Takai Y, Namatame C, Kuroda H, Misu T, Fujihara K, Aoki M (2023) Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids. Brain 146:3938\u20133948","journal-title":"Brain"},{"key":"12861_CR39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F, Wildemann B, Reindl M, In cooperation with the NeuromyelitisOptica Study G (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflamm 13:279","journal-title":"J Neuroinflamm"},{"key":"12861_CR40","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/acn3.52163","volume":"11","author":"M Reynolds","year":"2024","unstructured":"Reynolds M, Tan I, Nguyen K, Merheb V, Lee FXZ, Trewin BP, Lerch M, Shah S, Wolfe N, Buzzard K, Lechner-Scott J, Fabis-Pedrini M, Fok A, John N, Kneebone C, Yiannikas C, Brown DA, Kermode AG, Reddel S, Dale RC, Brilot F, Ramanathan S, Australasian MSG (2024) The clinical relevance of MOG antibody testing in cerebrospinal fluid. Ann Clin Transl Neurol\u00a011(9):2514\u20132519","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"12861_CR41","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000649","volume":"7","author":"A Cobo-Calvo","year":"2020","unstructured":"Cobo-Calvo A, d\u2019Indy H, Ruiz A, Collongues N, Kremer L, Durand-Dubief F, Rollot F, Casey R, Vukusic S, De Seze J, Marignier R (2020) Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: a multicenter cross-sectional study. Neurol Neuroimmunol Neuroinflamm 7(2):e649","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12861_CR42","volume":"11","author":"NN Kim","year":"2024","unstructured":"Kim NN, Champsas D, Eyre M, Abdel-Mannan O, Lee V, Skippen A, Chitre MV, Forsyth R, Hemingway C, Kneen R, Lim M, Ram D, Ramdas S, Wassmer E, West S, Wright S, Biswas A, Mankad K, Flanagan EP, Palace J, Rossor T, Ciccarelli O, Hacohen Y (2024) Pediatric MOG-Ab-associated encephalitis: supporting early recognition and treatment. Neurol Neuroimmunol Neuroinflamm 11:e200323","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12861_CR43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","volume":"19","author":"T Armangue","year":"2020","unstructured":"Armangue T, Olive-Cirera G, Martinez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Munoz-Batista M, Arino H, Gonzalez-Alvarez V, Felipe-Rucian A, Jesus Martinez-Gonzalez M, Cantarin-Extremera V, Concepcion Miranda-Herrero M, Monge-Galindo L, Tomas-Vila M, Miravet E, Malaga I, Arrambide G, Auger C, Tintore M, Montalban X, Vanderver A, Graus F, Saiz A, Dalmau J, Spanish Pediatric anti MOGSG (2020) Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 19:234\u2013246","journal-title":"Lancet Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12861-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12861-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12861-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:41:16Z","timestamp":1739637676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12861-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["12861"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12861-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Laura Cacciaguerra received speaker and consultant honoraria from ACCMED, Roche, BMS, Celgene, and Sanofi and travel support for conferences from Merck-Serono. She serves as Review Editor for Brain Health and Clinical Neuroscience (section of Frontiers in Human Neuroscience) and Clinical Neuroimaging (section of Frontiers in Neuroimaging). Elia Sechi received speaker honoraria and\/or support for attending scientific meetings from Alexion, Horizon, Novartis, Roche and UCB. He serves as an editorial board member for BMC Neurology and Frontiers in Neurology. Dr. Sechi is a member of the medical advisory board of the MOG project. Isabelle Komla-Soukha reports no disclosures. John J. Chen reports payment for consultation from UCB and Horizon. Carin Y. Smith reports no disclosures. Sarah M. Jenkins reports no disclosures. Kai Guo reports no disclosures. Vyanka Redenbaugh reports no disclosures. James P. Fryer reports no disclosures. Jan-Mendelt Tillema is Associate Editor for Journal of Child Neurology. Nisa Vorasoot reports no disclosures. Nanthaya Tisavipat reports no disclosures. Smathorn Thakolwiboon reports no disclosures. Divyanshu Dubey has consulted for UCB, Immunovant, Argenx, Arialys, and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. He has patents pending for KLHL11, LUZP4-IgG, SKOR2-IgG, and cavin-4-IgG as markers of neurologic autoimmunity. Dr. Dubey has received funding from the DOD (CA210208, PR220430). Anastasia Zekeridou has patents submitted for DACH1-IgG, PDE0A-IgG, CAMKV-IgG and Tenascin-R-IgG as biomarkers of paraneoplastic neurological autoimmunity; receives research funding from Roche not relevant to this manuscript and consulted for Alexion Pharmaceuticals without personal compensation. Andrew McKeon reported grants from the NIH (Grants RO1NS126227 and U01NS120901) during the conduct of the study; consulting fees from Janssen and Roche (all paid to Mayo Clinic) outside the submitted work; and had a patent for MAP1B antibody issued, a patent for Septins 5, 7, GFAP, PDE10A, KLHL11 antibodies pending, a patent for Septin antibodies and MAP1B antibodies with royalties paid. W. Oliver Tobin has received grants from the National Institutes of Health, and book royalties from the publication of Mayo Clinic Cases in Neuroimmunology (Mayo Clinic Scientific Press) 2022. Orhun H. Kantarci reports no disclosures. B. Mark Keegan served as a consultant to EMD Serono, is a member of the Center for Multiple Sclerosis and Autoimmune Research Mayo Clinic, receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases, and is an Editorial Board member of Multiple Sclerosis and Related Disorders. Deena A. Tajfirouz reports no disclosures. Kevin D. Chodnicki reports no disclosures. Jay Mandrekar reports no disclosures. Claudia F. Lucchinetti accrue revenue for a patent (no. 7101679) regarding aquaporin-4-associated antibodies for diagnosis of neuromyelitis optica and receives research support from the National MS Society, Biogen, and NIH. Sebastian A. Lopez-Chiriboga has served on advisory boards for Genentech and Horizon Therapeutics. Nabeela Nathoo reports no disclosures. Nycole K. Joseph reports no disclosures. Michelle F. Devine reports no disclosures. Jessica A. Sagen reports no disclosures. Sean J. Pittock has received personal compensation for serving as a consultant for Roche\/Genentech, Sage Therapeutics, Arialys and Astellas. He has received personal compensation for serving on scientific advisory boards or data safety monitoring boards for F. Hoffman-LaRoche AG, Genentech, Arialys and UCB. His institution has received compensation for serving as a consultant for Astellas, Alexion, and Viela Bio\/MedImmune. All compensation is paid to Mayo Clinic. He has received research support from Alexion, Viela Bio\/MedImmune, Roche\/Genentech and Adimmune. He has a patent, Patent# 8,889,102 (Application#12-678350, Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia)\u2014issued; a patent, Patent# 9,891,219B2 (Application#12-573942, Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive)-issued and from which he has received royalties and a patent for GFAP-IgG; Septin-5-IgG; MAP1B-IgG; Kelch-like protein 11; PDE10A pending. He is working as a consultant in the Mayo Clinic Neuroimmunology laboratory clinical service. The Mayo Clinic Neuroimmunology Laboratory commercially offers MOG-IgG testing, but revenue accrued does not contribute to salary, research support, or personal income. Philippe Cabre reports no disclosures. Eoin P. Flanagan has served on advisory boards for Alexion, Genentech and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune\/Viela-Bio\/Horizon Therapeutics. Dr Flanagan has received funding from the NIH (R01NS113828). Dr Flanagan is a member of the medical advisory board of the MOG project. Dr Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. A patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study\u00a0has been approved by the appropriate ethics committee and have therefore has\u00a0been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"118"}}